demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID 19 hospitalized
COVID-19 mild to moderate
anticoagulant X-COVID-19
anticoagulant, curative dose ATTACC, ACTIV-4a, and REMAP-CAP ...
heparin at therapeutic dose RAPID ...

1 studies excluded by filtering options 2

6405 Li [retracted], 2020 200excludedrisk of bias not avaialble